Effects of the Novel Formulated Forms of Curcumin on Tumor Growth Inhibition in Breast Cancer

Document Type : Review Article

Authors

1 PhD Candidate, Department of Medical Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Assistant Professor, Department of Genetics, Cancer Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Professor, Department of Obstetrics and Gynecology, Women’s Health Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

4 Associate Professor, Department of Oncology, Cancer Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

5 Assistant Professor, Department of Obstetrics and Gynecology, Women’s Health Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

6 Assistant Professor, Department of Radiation Therapy, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

7 Professor, Department of Physiology, Neurogenic Inflammation Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

8 Assistant Professor, Department of Medical Biochemistry, Metabolic Syndrome Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Abstract

Introduction: Breast cancer is the most common malignancy and the second leading cause of death due to cancer in women following lung cancer. Ample evidence has shown the antitumor activities of curcumin in breast cancer in preclinical and clinical trials. The anticancer effects of curcumin include the inhibition of cancer cell formation, angiogenesis, and tumor growth. Due to the low absorption of curcumin in the gastrointestinal tract, as well as its low water solubility, rapid metabolism, and high excretion, curcumin has low bioavailability. Therefore, using formulated curcumin could increase its bioavailability. The present study aimed to evaluate the effects of curcumin and its nano-formulated compositions in the prevention and treatment of breast cancer.  
Methods: In this review, data were collected via searching in databases such as PubMed, Scopus, Google Scholar, and Magiran to identify the related English and Persian articles published until 2016 using keywords such as nano-forms, clinical study, cancer, breast, and curcumin. In total, 40 studies were identified and reviewed.  
Results: Using formulated curcumin could increase its absorption and bioavailability, while it also enhances its effects on cancer cells, including breast cancer cells. Therefore, nano-formulated curcumin was observed to be effective in the prevention and treatment of breast cancer.  
Conclusion: Considering the higher bioavailability of the formulated compounds of curcumin compared to its free form and the low toxicity of this herbal medicine, curcumin could be used in combination with other anticancer medications in the treatment of breast cancer.

Keywords

References

  1. McPherson K, Steel CM, Dixon JM. Breast cancer-epidemiology, risk factors, and genetics. BMJ 2000; 321(7261):624-8.
  2. Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, et al. Breast cancer in Iran: an epidemiological review. Breast J 2007; 13(4):383-91.
  3. Perrone D, Ardito F, Giannatempo G, Dioguardi M, Troiano G, Lo Russo L, et al. Biological and therapeutic activities, and anticancer properties of curcumin. Exp Ther Med 2015; 10(5):1615-23.
  4. Agrawal DK, Mishra PK. Curcumin and its analogues: potential anticancer agents. Med Res Rev 2010; 30(5):818-60.
  5. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, et al. Curcumin suppresses the paclitaxel-induced nuclear factor-κB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 2005; 11(20):7490-8.
  6. Lv ZD, Liu XP, Zhao WJ, Dong Q, Li FN, Wang HB, et al. Curcumin induces apoptosis in breast cancer cells and inhibits tumor growth in vitro and in vivo. Int J Clin Exp Pathol 2014; 7(6):2818-24.
  7. Bahreyni A, Samani SS, Rahmani F, Behnam-Rassouli R, Khazaei M, Ryzhikov M, et al. Role of adenosine signaling in the pathogenesis of breast cancer. J Cell Physiol 2017; 233(3):1836-43.
  8. Hosseini M, Hassanian SM, Mohammadzadeh E, ShahidSales S, Maftouh M, Fayazbakhsh H, et al. Therapeutic potential of curcumin in treatment of pancreatic cancer: current status and future perspectives. J Cell Biochem 2017; 118(7):1634-8.
  9. Hosseini M, Hassanian SM, Mohammadzadeh E, ShahidSales S, Maftouh M, Fayazbakhsh H, et al. Therapeutic Potential of Curcumin in Treatment of Pancreatic Cancer: Current Status and Future Perspectives. Journal of cellular biochemistry. 2017;118(7):1634-8. Epub 2017/01/21.
  10. Prasad CP, Rath G, Mathur S, Bhatnagar D, Ralhan R. Potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/β-catenin signaling. Chem Biol Interact 2009; 181(2):263-71.
  11. Bahrami A, Hassanian SM, Khazaei M, Hasanzadeh M, Shahidsales S, Maftouh M, et al. The therapeutic potential of targeting tumor microenvironment in breast cancer: rational strategies and recent progress. J Cell Biochem 2018; 119(1):11-22.
  12. Bahrami A, Amerizadeh F, ShahidSales S, Khazaei M, Ghayour-Mobarhan M, Sadeghnia HR, et al. Therapeutic Potential of Targeting Wnt/beta-Catenin Pathway in Treatment of Colorectal Cancer: Rational and Progress. Journal of cellular biochemistry. 2017;118(8):1979-83. Epub 2017/01/22.
  13. Bachmeier BE, Mohrenz IV, Mirisola V, Schleicher E, Romeo F, Höhneke C, et al. Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFκB. Carcinogenesis 2008; 29(4):779-89.
  14. Asgharzadeh F, Rouzbahani R, Khazaei M. Chronic low-grade inflammation: etiology and its effects. J Isfahan Med Sch 2016; 34(379):408-21.
  15. Kim HI, Huang H, Cheepala S, Huang S, Chung J. Curcumin inhibition of integrin (α6β4)-dependent breast cancer cell motility and invasion. Cancer Prev Res 2008; 1(5):385-91.
  16. Mo N, Li ZQ, Li J, Cao YD. Curcumin inhibits TGF-β1-induced MMP-9 and invasion through ERK and Smad signaling in breast cancer MDA-MB-231 cells. Asian Pac J Cancer Prev 2012; 13(11):5709-14.
  17. Kim JM, Noh EM, Kwon KB, Kim JS, You YO, Hwang JK, et al. Curcumin suppresses the TPA-induced invasion through inhibition of PKCα-dependent MMP-expression in MCF-7 human breast cancer cells. Phytomedicine 2012; 19(12):1085-92.
  18. Tajbakhsh A, Hasanzadeh M, Rezaee M, Khedri M, Khazaei M, ShahidSales S, et al. Therapeutic potential of novel formulated forms of curcumin in the treatment of breast cancer by the targeting of cellular and physiological dysregulated pathways. Journal of cellular physiology. 2018;233(3):2183-92. Epub 2017/04/19.
  19. Li L, Braiteh FS, Kurzrock R. Liposome‐encapsulated curcumin. Cancer 2005; 104(6):1322-31.
  20. Lin YL, Liu YK, Tsai NM, Hsieh JH, Chen CH, Lin CM, et al. A Lipo-PEG-PEI complex for encapsulating curcumin that enhances its antitumor effects on curcumin-sensitive and curcumin-resistance cells. Nanomedicine 2012; 8(3):318-27.
  21. Dhule SS, Penfornis P, Frazier T, Walker R, Feldman J, Tan G, et al. Curcumin-loaded γ-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma. Nanomedicine 2012; 8(4):440-51.
  22. Gota VS, Maru GB, Soni TG, Gandhi TR, Kochar N, Agarwal MG. Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J Agric Food Chem 2010; 58(4):2095-9.
  23. Mulik RS, Mönkkönen J, Juvonen RO, Mahadik KR, Paradkar AR. Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis. Int J Pharm 2010; 398(1):190-203.
  24. Liu CH, Chang FY, Hung DK. Terpene microemulsions for transdermal curcumin delivery: effects of terpenes and cosurfactants. Colloids Surf B Biointerfaces 2011; 82(1):63-70.
  25. Sari T, Mann B, Kumar R, Singh RR, Sharma R, Bhardwaj M, et al. Preparation and characterization of nanoemulsion encapsulating curcumin. Food Hydrocolloids 2015; 43:540-6.
  26. Setthacheewakul S, Mahattanadul S, Phadoongsombut N, Pichayakorn W, Wiwattanapatapee R. Development and evaluation of self-microemulsifying liquid and pellet formulations of curcumin, and absorption studies in rats. Eur J Pharm Biopharm 2010; 76(3):475-85.
  27. Smithson KW, Millar DB, Jacobs LR, Gray GM. Intestinal diffusion barrier: unstirred water layer or membrane surface mucous coat? Science 1981; 214(4526):1241-4.
  28. Giori A, Franceschi F. Phospholipid complexes of curcumin having improved bioavailability. Tokyo: Indena SpA; 2007.
  29. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, et al. Efficacy and safety of Meriva (R), a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev 2010; 15(4):337-44.
  30. Semalty A, Semalty M, Rawat MS, Franceschi F. Supramolecular phospholipids–polyphenolics interactions: The PHYTOSOME® strategy to improve the bioavailability of phytochemicals. Fitoterapia 2010; 81(5):306-14.
  31. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 2012; 161(2):505-22.
  32. Fredenberg S, Wahlgren M, Reslow M, Axelsson A. The mechanisms of drug release in poly (lactic-co-glycolic acid)-based drug delivery systems--a review. Int J Pharm 2011; 415(1-2):34-52.
  33. Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 2011; 63(3):170-83.
  34. Misra R, Sahoo SK. Coformulation of doxorubicin and curcumin in poly (D, L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm 2011; 8(3):852-66.
  35. Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent‐incorporating polymer micelles. Cancer Sci 2009; 100(4):572-9.
  36. Lu Y, Park K. Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int J Pharm 2013; 453(1):198-214.
  37. Song L, Shen Y, Hou J, Lei L, Guo S, Qian C. Polymeric micelles for parenteral delivery of curcumin: preparation, characterization and in vitro evaluation. Colloid Surf A Physicochem Engine Aspects 2011; 390(1):25-32.
  38. Song Z, Feng R, Sun M, Guo C, Gao Y, Li L, et al. Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: Preparation, pharmacokinetics and distribution in vivo. J Colloid Interface Sci 2011; 354(1):116-23.
  39. Tang H, Murphy CJ, Zhang B, Shen Y, Sui M, Van Kirk EA, et al. Amphiphilic curcumin conjugate-forming nanoparticles as anticancer prodrug and drug carriers: in vitro and in vivo effects. Nanomedicine 2010; 5(6):855-65.
  40. Yang R, Zhang S, Kong D, Gao X, Zhao Y, Wang Z. Biodegradable polymer-curcumin conjugate micelles enhance the loading and delivery of low-potency curcumin. Pharm Res 2012; 29(12):3512-25.
  41. Mohanty C, Sahoo SK. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials 2010; 31(25):6597-611.
  42. Suwannateep N, Banlunara W, Wanichwecharungruang SP, Chiablaem K, Lirdprapamongkol K, Svasti J. Mucoadhesive curcumin nanospheres: biological activity, adhesion to stomach mucosa and release of curcumin into the circulation. J Control Release 2011; 151(2):176-82.
  43. Yallapu MM, Ebeling MC, Jaggi M, Chauhan SC. Plasma proteins interaction with curcumin nanoparticles: implications in cancer therapeutics. Curr Drug Metab 2013; 14(4):504-15.
  44. Boztas AO, Karakuzu O, Galante G, Ugur Z, Kocabas F, Altuntas CZ, et al. Synergistic interaction of paclitaxel and curcumin with cyclodextrin polymer complexation in human cancer cells. Mol Pharm 2013; 10(7):2676-83.
  45. D'Souza AA, Devarajan PV. Bioenhanced oral curcumin nanoparticles: role of carbohydrates. Carbohydr Polym 2016; 136:1251-8.
  46. Manju S, Sreenivasan K. Conjugation of curcumin onto hyaluronic acid enhances its aqueous solubility and stability. J Colloid And Interface Sci 2011; 359(1):318-25.
  47. Li J, Shin GH, Chen X, Park HJ. Modified curcumin with hyaluronic acid: combination of pro-drug and nano-micelle strategy to address the curcumin challenge. Food Res Int 2015; 69:202-8.
  48. Kesharwani P, Banerjee S, Padhye S, Sarkar FH, Iyer AK. Hyaluronic acid engineered nanomicelles loaded with 3,4-difluorobenzylidene curcumin for targeted killing of CD44+ stem-like pancreatic cancer cells. Biomacromolecules 2015; 16(9):3042-53.
  49. Parvathy KS, Negi PS, Srinivas P. Curcumin–amino acid conjugates: synthesis, antioxidant and antimutagenic attributes. Food Chem 2010; 120(2):523-30.
  50. Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z, et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 2008; 17(6):1411-7.
  51. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008; 132(3):171-83.
  52. Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release 2012; 157(2):168-82.
  53. Paşcalău V, Soritau O, Popa F, Pavel C, Coman V, Perhaita I, et al. Curcumin delivered through bovine serum albumin/polysaccharides multilayered microcapsules. J Biomater Appl 2016; 30(6):857-72.
  54. Kim TH, Jiang HH, Youn YS, Park CW, Tak KK, Lee S, et al. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity. Int J Pharm 2011; 403(1-2):285-91.
  55. Esmaili M, Ghaffari SM, Moosavi-Movahedi Z, Atri MS, Sharifizadeh A, Farhadi M, et al. Beta casein-micelle as a nano vehicle for solubility enhancement of curcumin; food industry application. LWT-Food Sci Technol 2011; 44(10):2166-72.
  56. Zhang Z, Zhang R, Zou L, Chen L, Ahmed Y, Al Bishri W, et al. Encapsulation of curcumin in polysaccharide-based hydrogel beads: impact of bead type on lipid digestion and curcumin bioaccessibility. Food Hydrocolloids 2016; 58:160-70.
  57. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A, et al. Polymeric nanoparticle-encapsulated curcumin (" nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology 2007; 5:3.
  58. Bisht S, Mizuma M, Feldmann G, Ottenhof NA, Hong SM, Pramanik D, et al. Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer. Mol Cancer Ther 2010; 9(8):2255-64.
  59. Lim KJ, Bisht S, Bar EE, Maitra A, Eberhart CG. A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol Ther 2011; 11(5):464-73.
  60. He Y, Huang Y, Cheng Y. Structure evolution of curcumin nanoprecipitation from a micromixer. Crystal Growth Design 2010; 10(3):1021-4.
  61. Wang Z, Leung MH, Kee TW, English DS. The role of charge in the surfactant-assisted stabilization of the natural product curcumin. Langmuir 2009; 26(8):5520-6.
  62. Hasan M, Belhaj N, Benachour H, Barberi-Heyob M, Kahn C, Jabbari E, et al. Liposome encapsulation of curcumin: physico-chemical characterizations and effects on MCF7 cancer cell proliferation. Int J Pharm 2014; 461(1-2):519-28.
  63. Palange AL, Di Mascolo D, Carallo C, Gnasso A, Decuzzi P. Lipid–polymer nanoparticles encapsulating curcumin for modulating the vascular deposition of breast cancer cells. Nanomedicine 2014; 10(5):991-1002.
  64. Thamake SI, Raut SL, Gryczynski Z, Ranjan AP, Vishwanatha JK. Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer. Biomaterials 2012; 33(29):7164-73.
  65. Tabatabaei Mirakabad FS, Akbarzadeh A, Milani M, Zarghami N, Taheri-Anganeh M, Zeighamian V, et al. A comparison between the cytotoxic effects of pure curcumin and curcumin-loaded PLGA-PEG nanoparticles on the MCF-7 human breast cancer cell line. Artif Cells Nanomed Biotechnol 2016; 44(1):423-30.
  66. Liu L, Sun L, Wu Q, Guo W, Li L, Chen Y, et al. Curcumin loaded polymeric micelles inhibit breast tumor growth and spontaneous pulmonary metastasis. Int J Pharm 2013; 443(1-2):175-82.
  67. Alizadeh AM, Sadeghizadeh M, Najafi F, Ardestani SK, Erfani-Moghadam V, Khaniki M, et al. Encapsulation of curcumin in diblock copolymer micelles for cancer therapy. Biomed Res Int 2015; 2015:824746.
  68. Shiri S, Alizadeh AM, Baradaran B, Farhanghi B, Shanehbandi D, Khodayari S, et al. Dendrosomal curcumin suppresses metastatic breast cancer in mice by changing m1/m2 macrophage balance in the tumor microenvironment. Asian Pac J Cancer Prev 2014; 16(9):3917-22.
  69. Debnath S, Saloum D, Dolai S, Sun C, Averick S, Raja K, et al. Dendrimer-curcumin conjugate: a water soluble and effective cytotoxic agent against breast cancer cell lines. Anticancer Agents Med Chem 2013; 13(10):1531-9.
  70. Farhangi B, Alizadeh AM, Khodayari H, Khodayari S, Dehghan MJ, Khori V, et al. Protective effects of dendrosomal curcumin on an animal metastatic breast tumor. Eur J Pharmacol 2015; 758:188-96.

Farhangi B, Dehghan Eamj, Soleimani N, Salehi Z. The Survey Of Cytotoxic Effect Of Dendrosomal Nano Curcumin On 4t1 Metastatic Model Of Breast Cancer. 2014.

The Iranian Journal of Obstetrics, Gynecology and Infertility
Volume 21, Issue 2
April 2018
Pages 84-75

Files

Share

How to cite

Statistics